enGene Holdings Inc

Chart & Performance

D1W1MN

P/E

7.63

P/S

—

EPS

1.08

Div Yield, %

—

Shrs. gr., 5y

—

Rev. gr., 5y

Revenues

Net income

55m

CFO

-48m

L+95.13%

Dividend

Dec 01, 20140.14 USD/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

URL

https://engene.com/

IPO date

Dec 10, 2021

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2024‑10	2023‑10	2022‑10	2021‑10	2020‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT